NovaBay Pharmaceuticals stock doubles as NBY volatility flares again — what to watch next

NovaBay Pharmaceuticals stock doubles as NBY volatility flares again — what to watch next

New York, January 10, 2026, 18:35 EST — Market closed

  • Shares of NovaBay Pharmaceuticals surged roughly 103% to close Friday at $19.16
  • This surge arrives as investors re-examine the company’s asset sales and wind-down language in its filings
  • Attention shifts to Monday’s reopening and the upcoming earnings report scheduled next

Shares of NovaBay Pharmaceuticals Inc soared on Friday, closing up roughly 103% at $19.16. Over 10 million shares changed hands, market data showed.

NovaBay is back on momentum screens before the next U.S. session, trading in a price range unseen for over a year.

Why it matters now: NovaBay’s size means its price often moves on volume, not news. When that shift hits before a weekend, the following open becomes a gauge of who’s left to buy.

The stock moved between $9.69 and $19.95 in regular trading, then was last seen near $20.50 after hours on Friday, data showed.

NovaBay revealed in its latest quarterly filing that it sold its main “Avenova” trademark to PRN Physician Recommended Nutriceuticals, with the deal effective Jan. 17, 2025. The company also offloaded the “PhaseOne” and “NeutroPhase” U.S. trademarks, effective Jan. 8, 2025. The board decided the best path to unlock remaining value is pursuing dissolution and putting that plan to shareholders. At the end of June 2025, NovaBay reported $5.3 million in cash and equivalents, and as of Aug. 12, 2025, it had 5.82 million shares outstanding. (SEC)

Last August, NovaBay announced a one-time special cash dividend of $0.80 per share. CEO David Lazar described it as “reflecting our commitment to creating and returning value directly to our stockholders.” (BioSpace)

A separate insider filing detailed pre-funded warrants tied to an investor deal, which can be exercised for common shares after Jan. 1, 2026, pending shareholder approval. These pre-funded warrants let buyers pay nearly the full price upfront and convert to shares at a later date. (SEC)

That very setup driving steep rallies can just as easily reverse. A change in outlook on a wind-down, adjustments to capital structure, or even straightforward profit-taking could slam a thin tape suddenly and sharply.

Markets reopen Monday, Jan. 12, with traders eyeing if volume holds steady and any fresh company disclosures emerge following last week’s jump. According to TipRanks, NovaBay’s next earnings report is due March 26, after the close.

Stock Market Today

  • Opendoor Rebound Hopes Rise as Trump Mortgage-Bond News Spurs Housing Stocks
    January 11, 2026, 11:37 AM EST. Opendoor Technologies (OPEN) has drawn renewed attention after a Trump plan to repurchase about $200 billion in mortgage securities spurred buying in housing stocks. The late-2023 meme-stock surge for Opendoor has cooled among retail investors, but the latest government-bond news could rekindle interest. The plan would have Fannie Mae and Freddie Mac buy the securities to push down rates, a move traders linked to housing equities welcomed with a roughly 5% intraday gain. Opendoor traded near $7.29, with a $7.0B market cap and a 52-week range of $0.51-$10.87. Some see potential for further sentiment-driven moves; others warn gains may diverge from fundamentals. Existing holders may ride the near term; new buyers should tread carefully, given the stock's volatility and valuation gaps.
Plug Power stock (PLUG) slides after TD Cowen downgrade as Walmart deal and dilution vote near
Previous Story

Plug Power stock (PLUG) slides after TD Cowen downgrade as Walmart deal and dilution vote near

Rubrik stock slips again after CFO sale filing — what to watch before Monday’s open
Next Story

Rubrik stock slips again after CFO sale filing — what to watch before Monday’s open

Go toTop